key: cord-0703038-6uwstdak
authors: van Riel, Debby; Embregts, Carmen W.E.; Sips, Gregorius J.; van den Akker, Johannes P.C.; Endeman, Henrik; van Nood, Els; van Kampen, Jeroen; Molenkamp, Richard; Koopmans, Marion; van de Vijver, David; GeurtsvanKessel, Corine H.
title: Temporal kinetics of RNAemia and associated systemic cytokines in hospitalized COVID-19 patients
date: 2020-12-18
journal: bioRxiv
DOI: 10.1101/2020.12.17.423376
sha: 99923e09aa5bcc720727101df21ac6fa75efa837
doc_id: 703038
cord_uid: 6uwstdak

COVID-19 is associated to a wide range of extra-respiratory complications, of which the pathogenesis is currently not fully understood. In this study we report the temporal kinetics of viral RNA and inflammatory cytokines and chemokines in serum during the course of COVID-19. We show that a RNAemia occurs more frequently and lasts longer in patients that develop critical disease compared to patients that develop moderate or severe disease. Furthermore we show that concentrations of IL-10 and MCP-1—but not IL-6—are associated with viral load in serum. However, higher levels of IL-6 were associated with the development of critical disease. The direct association of inflammatory cytokines with viral load or disease severity highlights the complexity of systemic inflammatory response and the role of systemic viral spread.

COVID-19 has been associated with a wide range of extra-respiratory complications, including neurologic, cardiac, and thromboembolic complications. The pathogenesis of these extra-respiratory complications is not fully understood but several mechanisms are thought to contribute, including the systemic spread of SARS-CoV-2 and systemic inflammatory cytokines (Gupta et al., 2020) . Even though SARS-CoV-2 viral RNA and inflammatory cytokines have been detected in the blood, their kinetics during infection are poorly understood and it is unclear if either RNAemia or inflammatory cytokines are associated with each other or with other disease parameters. We hypothesize that RNAemia occurs frequently during severe and that it contributes to the systemic cytokine responses. Therefore we aimed to get insight in the kinetics of SARS CoV-2 RNAemia and the associated systemic inflammatory response.

Diagnostic specimen of twenty patients (16 male, 4 female), hospitalized at the Erasmus MC in the Netherlands in March and April 2020, were analyzed. Ten patients developed moderate or severe disease (grouped together) and 10 critical disease, according to NIH disease severity guidelines (https://www.covid19treatmentguidelines.nih.gov/overview/management-of-covid-19). One or more underlying diseases were present in 19 patients which included cardiovascular diseases (11), diabetes (9), previous cerebro-vascular accident (4), previous respiratory disease (3), cancer (3), solid organ transplantation (2), kidney failure (1), psychosis (1) or sarcoidosis (1). None of the patients received dexamesthasone during the course of disease. Further patient characteristics are included in Supplemental Table 1 . A total of 176 serum samples were analyzed and a paired RT ([naso]pharyngeal swab or sputum) was available for 131 specimens (Table S2) . Viral RNA was measured by qPCR for the E gene in all serum and RT samples as described previously (Corman et al., 2020) . RNAemia was detected in 50% and 90% of the patients with respectively moderate/severe or critical disease. The duration of the RNAemia per patient could not be determined, since samples early after disease onset were not available for all patients, but RNAemia was more frequently detected from 11 days post disease onset (dpd) in patients who developed critical disease (OR 4.65 CI 1.05-20.64; p = 0.038; Figure 1A , Table S2 ), as was calculated using generalized estimated equations, corrected for repeated samples within patients. Furthermore, independent of disease severity, RNAemia was associated with a ct value <30 in paired RT samples (OR 9.47, CI 3.08-29.07; p=0.009) and < 11 dpd (OR 4.61, p=0.001; figure 1B) . In this study there was no correlation between RNAemia and age (OR 1.0, CI 0.99-1.01; p=0.31) or BMI (OR1.0, CI 0.9-1.2; p=0.58). Virus could not be isolated from serum samples, but since these had been collected for molecular and serological diagnostics, the sample handling and storage was most likely suboptimal for virus culture. In addition, we have previously shown that virus is difficult to culture from samples with an ct value of 27 (van Kampen J.J.A, 2020).

Next, we used a 13-plex cytometric bead assay to determine kinetics of the inflammatory cytokines and chemokines IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IP-10, IFNγ, TNFα, MCP-1 and TGFβ in serum of patients up to 21 dpd ( Fig S1) . All tested cytokines were significantly upregulated during the course of infection, with the exception of IL-4, IL-12p70 and TGFβ, which were therefore excluded from further analysis. IFNγ, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-17A, IP-10, MCP-1 and TNFα were induced during the course of disease ( Figure 1C ), although large differences were observed among individual patients. Overall, a dynamic response was observed in the majority of patients ( Figure S1 ). Generalized estimated equations, corrected for repeated sampling within patients, were used to determine associations of individual cytokines with RNAemia, a ct RT <30, disease severity and outcome, and period after disease onset. Of all cytokines and chemokines only IFNγ was associated with a disease period of ≤10 days in both uni-and multivariate analysis (Table, Figure 1C ).

First, we determined which cytokines or chemokines were associated with the viral load in serum or RT sample. A RNAemia was associated with increased levels of IL-1β, IL-6, IL-8, IL-10, IP-10 and MCP-1 in a univariate analysis. Subsequent multivariate analyses, adjusting for the ct value in the RT, showed that Il-10 and MCP-1 were independently associated with RNAemia (Table, Figure S2A ). In a univariate analysis, ct value <30 in the RT was associated with increased serum levels of IFNγ, IL-1β, IL-2, IL-6, IL-8, IL-10, IP-10 and MCP-1 compared to a ct value >31 in the RT, and with increased levels of IFNγ and IL-1β in a multivariate analysis (Table, Figure S2B ).

Next, we determined which cytokines or chemokines were associated with the development of critical disease and death as outcome. Patients that developed critical disease had significantly higher levels of IL-1β and IL-6 compared to patients that developed moderate or severe disease (Table, Figure S3A ). Death as an outcome was not associated with elevated levels of any of the cytokine included in this study in the multivariate analyses (Table, Figure S3B ).

Altogether, this study shows the presence of RNAemia in critically ill COVID-19 patients. The overall detection of RNAemia in 70% of patients included in this study is higher than in most other reports (Hogan et al., 2020 , Fajnzylber et al., 2020 . This is likely due to the fact that all patients included in this study were hospitalized with moderate, severe or critical disease and the fact that we analyzed samples throughout the course of disease. The fact that a RNAemia is detected at later time points post disease onset in patients that develop critical disease, together with the detection of SARS-CoV-2 in extrarespiratory tissues (Gupta et al., 2020) , suggests the systemic spread of SARS-CoV-2 contributes to the pathogenesis of severe COVID-19.

The role of systemic cytokines during the course of COVID-19 is only partly understood. In line with previous studies we show that higher levels of IL-6 are associated with the development of more severe disease (Del Valle et al., 2020 , Zhang et al., 2020 . However, IL-6 is not directly associated with viral load in either serum or the respiratory tract in our study, which suggest that IL-6 production is not directly triggered by virus replication. In contrast, IL-10, MCP-1, IL-1β and IFNγ were associated with either viral RNA in serum or RT suggesting that these were triggered-either directly or indirectly-by virus replication. This suggests that the systemic cytokine response is complex, but is at least in part directly Individual cytokines plotted against the day post disease onset. * refers to significant higher levels in multivariate analyses < 10 dpd compared to > 10 dpd (C). culture and qPCR on respiratory tract specimen) were extracted from our diagnostic laboratory information management system. In addition, following information was extracted from the electronic patient files: date of onset of symptoms, disease severity (hospitalized on ICU with mechanical ventilation, hospitalized on ICU with oxygen therapy, hospitalized to ward with oxygen therapy, hospitalized to ward without oxygen therapy), whether the patients were still alive or not when they were discharged.

All patient specimen and data used in this study were collected in the context of routine clinical patient care. Additional analyses were performed only on surplus of patient material collected in the context of routine clinical patient care. Our institutional review board approved the use of these data and samples (METC-2015-306) . METC-2015-306 is a generic protocol to study viral diseases. Informed consent was waived by the privacy knowledge office of the Erasmus MC.

Systemic cytokines were quantified in all patients' sera up to 21 dpd. Sera were analysed in duplo using the 13-plex Human essential immune Legendplex panel (Biolegend). A standard cytokine cocktail was taken along in duplo to allow for quantification of the cytokine concentrations. The cytometric bead assay was performed on a FACSLyric (BD) and the data were analysed using the Legendplex data analysis software. 

An inflammatory cytokine signature predicts COVID-19 severity and survival

SARS-CoV-2 viral load is associated with increased disease severity and mortality

Extrapulmonary manifestations of COVID-19

High Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease

Viral and host factors related to the clinical outcome of COVID-19

The authors declare no competing interests